Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Parikh

Showing results (601-610 of 616) with videos related to

Pageof 62
Sort By:
The New England Journal of Medicine|February 5, 2015
Tenofovir-based preexposure prophylaxis for HIV infection among African womenJeanne M Marrazzo, Gita Ramjee, Barbra A Richardson, et al.
Journal of the International AIDS Society|August 21, 2025
A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South AfricaUrvi M Parikh, Lauren D Kudrick, Lisa Levy, et al.
The Journal of Infectious Diseases|February 17, 2026
Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune ResponsesDavey Smith, Isabelle R Weir, Sydney Ramirez, et al.
The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.
Journal of Medicinal Chemistry|April 13, 2001
A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptorR J DeVita, T F Walsh, J R Young, et al.
Medrxiv : the Preprint Server for Health Sciences|September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyManish C Choudhary, Kara W Chew, Rinki Deo, et al.
The Journal of Infectious Diseases|November 16, 2023
Prospective Assessment of Humoral and Cellular Immune Responses to a Third COVID-19 mRNA Vaccine Dose Among Immunocompromised IndividualsGhady Haidar, Jacob C Hodges, Andrew Bilderback, et al.
South Asian Journal of Cancer|January 5, 2022
Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in IndiaPurvish M Parikh, Gouri Shankar Bhattacharyya, Ghanshyam Biswas, et al.
Eclinicalmedicine|May 31, 2019
Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence AnalysisBenjamin Chimukangara, Richard J Lessells, Soo-Yon Rhee, et al.
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Pageof 62

Showing results (601-610 of 616) with videos related to

Sort By:
Pageof 62
The New England Journal of Medicine|February 5, 2015
Tenofovir-based preexposure prophylaxis for HIV infection among African womenJeanne M Marrazzo, Gita Ramjee, Barbra A Richardson, et al.
Journal of the International AIDS Society|August 21, 2025
A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South AfricaUrvi M Parikh, Lauren D Kudrick, Lisa Levy, et al.
The Journal of Infectious Diseases|February 17, 2026
Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune ResponsesDavey Smith, Isabelle R Weir, Sydney Ramirez, et al.
The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.
Journal of Medicinal Chemistry|April 13, 2001
A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptorR J DeVita, T F Walsh, J R Young, et al.
Medrxiv : the Preprint Server for Health Sciences|September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyManish C Choudhary, Kara W Chew, Rinki Deo, et al.
The Journal of Infectious Diseases|November 16, 2023
Prospective Assessment of Humoral and Cellular Immune Responses to a Third COVID-19 mRNA Vaccine Dose Among Immunocompromised IndividualsGhady Haidar, Jacob C Hodges, Andrew Bilderback, et al.
South Asian Journal of Cancer|January 5, 2022
Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in IndiaPurvish M Parikh, Gouri Shankar Bhattacharyya, Ghanshyam Biswas, et al.
Eclinicalmedicine|May 31, 2019
Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence AnalysisBenjamin Chimukangara, Richard J Lessells, Soo-Yon Rhee, et al.
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Pageof 62